Design, parallel synthesis and SAR of novel urotensin II receptor agonists

European Journal of Medicinal Chemistry

Volumn 42, Issue 2, 2007, Pages 276-285

  Lehmann, Fredrik ^a   Lake, Lisa ^a   Currier, Erika A ^c   Olsson, Roger ^b   Hacksell, Uli ^c   Luthman, Kristina ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ACADIA Pharmaceuticals AB   (Sweden)

^c ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

Amidation; Library synthesis; Solid supported reagents; Structure activity relationships; Urotensin II

Indexed keywords

1 (2 NAPHTHYL) 3 DIMETHYLAMINOPROPYLAMINE; 1 (4 CHLOROPHENYL) 3 DIMETHYLAMINOPROPYLAMINE; 4 TRIFLUOROMETHYLCINNAMIC AMIDE DERIVATIVE; AMIDE; FL 104; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR AGONIST;

AGONIST; AMIDATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NAPHTHALENES; NIH 3T3 CELLS; PROPYLAMINES; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847107720     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.09.015     Document Type: Article

References (22)

1. Lehmann F., Pettersen A., Currier E.A., Olsson R., Sherbukhin V., Hacksell U., and Luthman K. J. Med. Chem. 49 (2006) 2232-2240
2. Russell F.D. Pharmacol. Ther. 103 (2004) 223-243
3. Kruger S., Graf J., Kunz D., Stickel T., Merx M.W., Hanrath P., and Janssens U. Eur. J. Heart Fail. 7 (2005) 475-478
4. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Atherosclerosis 176 (2004) 117-123
5. Douglas S., Dhanak D., and Johns D.G. Trends Pharmacol. Sci. 25 (2004) 76-85
6. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., Satoh J., and Oka Y. Diabetologia 46 (2003) 972-976
7. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., and Gilbert R.E. Am. J. Kidney Dis. 44 (2004) 826-831
8. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. J. Med. Chem. 45 (2002) 1799-1805
9. Jin J., Dhanak D., Knight S.D., Widdowson K., Aiyar N., Naselsky D., Sarau H.M., Foley J.J., Schmidt D.B., Bennett C.D., Wang B., Warren G.L., Moore M.L., Keenan R.M., Rivero R.A., and Douglas S.A. Bioorg. Med. Chem. Lett. 15 (2005) 3229-3232
10. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S.S., Fischli W., Hess P., Mathys B., Morrison K., Müller C., Müller C., Nayler O., Qiu C.B., Rey M., Scherz M.W., Velker J., Weller T., Xi J.F., and Ziltener P. J. Pharmacol. Exp. Ther. 311 (2004) 204-212
11. Lehmann F., Currier E.A., Olsson R., Hacksell U., and Luthman K. Bioorg. Med. Chem. 13 (2005) 3057-3068
12. Doggrell S.A. Expert Opin. Investig. Drugs 13 (2004) 479-487
13. Lehmann F., Pilotti A., and Luthman K. Mol. Divers. 7 (2003) 145-152
14. Ritter J.J., and Minieri P.P. J. Am. Chem. Soc. 70 (1948) 4045-4048
15. Dardonville C., and Brun R. J. Med. Chem. 47 (2004) 2296-2307
16. Spalding T.A., Burstein E.S., Jorgensen H.B., Hill-Eubanks D., and Brann M.R. Life Sci. 56 (1995) 1021
17. Bräuner-Osborne H., and Brann M.R. Eur. J. Pharmacol. 295 (1996) 93-102
18. Burstein E.S., Bräuner-Osborne H., Spalding T.A., Conklin B.R., and Brann M.R. J. Neurochem. 68 (1997) 525-533
19. Burstein E.S., Spalding T.A., and Brann M.R. Mol. Pharmacol. 51 (1997) 312-319
20. Burstein E.S., Piu F., Ma J.-N., Weissman J.T., Currier E.A., Nash N.R., Weiner D.M., Spalding T.A., Schiffer H.H., Del Tredici A.L., and Brann M.R. Curr. Pharm. Des. 12 (2006) 1717-1729
21. Brkovic A., Hattenberger A., Kostenis E., Klabunde T., Flohr S., Kurz M., Bourgault S., and Fournier A. J. Pharmacol. Exp. Ther. 306 (2003) 1200-1209
22. Douglas S.A., Behm D.J., Aiyar N.V., Naselsky D., Disa J., Brooks D.P., Ohlstein E.H., Gleason J.G., Sarau H.M., Foley J.J., Buckley P.T., Schmidt D.B., Wixted W.E., Widdowson K., Riley G., Jin J., Gallagher T.F., Schmidt S.J., Ridgers L., Christmann L.T., Keenan R.M., Knight S.D., and Dhanak D. Br. J. Pharmacol. 145 (2005) 620-635